| Literature DB >> 18825314 |
Joanna Fraczek1, Sarah Deleu, Aneta Lukaszuk, Tatyana Doktorova, Dirk Tourwé, Albert Geerts, Tamara Vanhaecke, Karin Vanderkerken, Vera Rogiers.
Abstract
The vast majority of preclinical studies of HDAC inhibitors (HDAC-I) focus on the drug-target (cancer) cell interaction, whereas little attention is paid to the effects on non-target healthy cells, which could provide decisive information to eliminate potential cytotoxic compounds at a very early stage during drug development. In the current study we used cultures of primary rat hepatocytes as a read out system to select for the most potent HDAC-I in the group of structural analogues of an archetypal HDAC-I, namely Trichostatin A. This kind of approach allowed selecting compounds with high biological activity and with no apparent toxicity towards cultured hepatocytes.Entities:
Mesh:
Substances:
Year: 2008 PMID: 18825314 DOI: 10.1007/s10637-008-9180-x
Source DB: PubMed Journal: Invest New Drugs ISSN: 0167-6997 Impact factor: 3.850